Literature DB >> 18638454

Inflammation stimulates the expression of PCSK9.

Kenneth R Feingold1, Arthur H Moser, Judy K Shigenaga, Sophie M Patzek, Carl Grunfeld.   

Abstract

Inflammation induces marked changes in lipid and lipoprotein metabolism. Proprotein convertase subtilisin kexin 9 (PCSK9) plays an important role in regulating LDL receptor degradation. Here, we demonstrate that LPS decreases hepatic LDL receptor protein but at the same time hepatic LDL receptor mRNA levels are not decreased. We therefore explored the effect of LPS on PCSK9 expression. LPS results in a marked increase in hepatic PCSK9 mRNA levels (4h 2.5-fold increase; 38h 12.5-fold increase). The increase in PCSK9 is a sensitive response with 1microg LPS inducing a (1/2) maximal response. LPS also increased PCSK9 expression in the kidney. Finally, zymosan and turpentine, other treatments that induce inflammation, also stimulated hepatic expression of PCSK9. Thus, inflammation stimulates PCSK9 expression leading to increased LDL receptor degradation and decreasing LDL receptors thereby increasing serum LDL, which could have beneficial effects on host defense.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638454      PMCID: PMC2571081          DOI: 10.1016/j.bbrc.2008.07.023

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

Review 1.  The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor.

Authors:  M S Brown; J L Goldstein
Journal:  Cell       Date:  1997-05-02       Impact factor: 41.582

2.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

Authors:  Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

3.  Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.

Authors:  Florent Lalanne; Gilles Lambert; Marcelo J A Amar; Maud Chétiveaux; Yassine Zaïr; Anne-Laure Jarnoux; Khadija Ouguerram; José Friburg; Nabil G Seidah; H Bryan Brewer; Michel Krempf; Philippe Costet
Journal:  J Lipid Res       Date:  2005-03-01       Impact factor: 5.922

4.  Discordant regulation of proteins of cholesterol metabolism during the acute phase response.

Authors:  K R Feingold; A S Pollock; A H Moser; J K Shigenaga; C Grunfeld
Journal:  J Lipid Res       Date:  1995-07       Impact factor: 5.922

5.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

6.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

7.  NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Authors:  Suzanne Benjannet; David Rhainds; Rachid Essalmani; Janice Mayne; Louise Wickham; Weijun Jin; Marie-Claude Asselin; Josée Hamelin; Mathilde Varret; Delphine Allard; Mélanie Trillard; Marianne Abifadel; Angie Tebon; Alan D Attie; Daniel J Rader; Catherine Boileau; Louise Brissette; Michel Chrétien; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

8.  Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.

Authors:  Geneviève Dubuc; Ann Chamberland; Hanny Wassef; Jean Davignon; Nabil G Seidah; Lise Bernier; Annik Prat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-06-03       Impact factor: 8.311

9.  Repression of farnesoid X receptor during the acute phase response.

Authors:  Min Sun Kim; Judy Shigenaga; Art Moser; Kenneth Feingold; Carl Grunfeld
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

10.  Endotoxin suppresses rat hepatic low-density lipoprotein receptor expression.

Authors:  W Liao; M Rudling; B Angelin
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

View more
  67 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder.

Authors:  Ji Soo Lee; Daniel Rosoff; Audrey Luo; Martha Longley; Monte Phillips; Katrin Charlet; Christine Muench; Jeesun Jung; Falk W Lohoff
Journal:  Alcohol Clin Exp Res       Date:  2019-05-03       Impact factor: 3.455

Review 3.  Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Authors:  José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

4.  Circulating PCSK9 is lowered acutely following surgery.

Authors:  Irena Druce; Hussein Abujrad; Seham Chaker; Hilary Meggison; Andrew Hill; Angela Raymond; Janice Mayne; Teik Chye Ooi
Journal:  J Clin Lab Anal       Date:  2017-11-17       Impact factor: 2.352

5.  Cardiometabolic risk factors are associated with immune cell mitochondrial respiration in humans.

Authors:  Theodore M DeConne; Eric R Muñoz; Faria Sanjana; Joshua C Hobson; Christopher R Martens
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-07-17       Impact factor: 4.733

6.  Contribution of aorta glycosaminoglycans and PCSK9 to hyperlipidemia in experimental rabbits: the role of 10-dehdrogingerdione as effective modulator.

Authors:  Mohamed M Elseweidy; Sahar E Elswefy; Nahla N Younis; Shaden Tarek
Journal:  Mol Biol Rep       Date:  2019-05-02       Impact factor: 2.316

Review 7.  Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.

Authors:  Angelos D Karagiannis; Martin Liu; Peter P Toth; Shijia Zhao; Devendra K Agrawal; Peter Libby; Yiannis S Chatzizisis
Journal:  Curr Atheroscler Rep       Date:  2018-03-10       Impact factor: 5.113

8.  Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.

Authors:  Zufeng Ding; Shijie Liu; Xianwei Wang; Xiaoyan Deng; Yubo Fan; Changqing Sun; Yannian Wang; Jawahar L Mehta
Journal:  Antioxid Redox Signal       Date:  2015-01-08       Impact factor: 8.401

Review 9.  The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.

Authors:  Jason V Baker; W Keith Henry; James D Neaton
Journal:  Curr Opin HIV AIDS       Date:  2009-05       Impact factor: 4.283

10.  Inflammation impairs reverse cholesterol transport in vivo.

Authors:  Fiona C McGillicuddy; Margarita de la Llera Moya; Christine C Hinkle; Michelle R Joshi; Elise H Chiquoine; Jeffrey T Billheimer; George H Rothblat; Muredach P Reilly
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.